



Intranasal delivery is gaining importance in drug delivery development, and goes beyond the topical treatment of local conditions in the nose and sinuses. **It represents an attractive route for the treatment of neurological diseases, for children and elderly, or needle-free vaccination.**

MetP Pharma AG, Emmetten, Switzerland (<http://mattern-pharma.com>) has developed a proprietary drug delivery platform consisting of a semi-solid composition filled into mono-dose devices for intranasal application, and a high-speed filling machine for the devices (design: Harro Höfliger Verpackungs-maschinen GmbH).

MetPs mono-dose containers possess a remarkable high dosage uniformity ($\pm 3\%$), no priming step is required which could create application errors and no special head positions/breathing. The dosing volume can be adjusted between 50 – 150 μl . There is no tip contamination as with multi-dose devices and the device is easy to qualify compared to spray systems (one plastic material, no spray mechanism, single use). Further and most importantly for patient and compliance, the device is small, light and easy to handle.

For clients and for its own pipeline MetP targets the prescription and OTC markets. For example, well-proven and shelved molecules can be re-examined, re-positioned and re-profiled.